Login
Eloxx Pharmaceuticals, Inc. logo

Eloxx Pharmaceuticals, Inc.

eloxxpharma.com

What Do They Do?

Develops small-molecule drug candidates for rare genetic kidney diseases and, through a partner, rare skin diseases.

Who Are Their Customers?

Almirall is the customer for Eloxx’s license and service revenue and develops and commercializes ZKN-013 under an exclusive global rights agreement.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q2 FY2026, the three months to Jun 30, 2026
Net income
▼ −138% (Loss)
vs −$1.9M in Q2 FY2025

Partnered skin-disease program The skin-disease candidate moved from Eloxx's own development pipeline to an exclusive global rights arrangement: Almirall is responsible for its development and commercialization, whereas the older report described Eloxx advancing it for rare skin diseases and FAP.

Stated development focus The older report listed cystic fibrosis, FAP and oncology work alongside Alport and skin-disease programs; the latest identifies rare kidney diseases and partnered rare skin diseases as immediate priorities.

Who Do They Compete With?

Competes with Travere Therapeutics, River Renal, Bayer, Boehringer Ingelheim, Otsuka, AstraZeneca, Vertex Pharmaceuticals, Novartis, PYC Therapeutics, AbbVie, GSK, XORTX Therapeutics, Maze Therapeutics, Krystal Biotech, Abeona Therapeutics, Chiesi, Castle Creek, RHEACELL, and Inmune Bio

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support